ArticleSpartan medical research journal2025
Association between Timing of COVID-19 Diagnosis in Pregnancy and Maternal-Fetal Outcomes: A Retrospective Study.
Article in Spartan medical research journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Advancing Research, Education, and Clinical Practice: Insights from Evidence-Based Care and Interdisciplinary Scholarship.Spartan medical research journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the relationship between COVID-19 diagnosis timing during pregnancy and adverse maternal and fetal outcomes.
methodsPregnant women diagnosed with COVID-19 by a nasopharyngeal swab SARS-CoV-2 PCR between January 1, 2021, and December 31, 2021, irrespective of the pregnancy outcome, were included in the study. Patients not diagnosed with COVID-19 were included as a comparison group. The timing of COVID diagnosis was categorized by trimester (first trimester, <13 weeks; second trimester, 13 to <27 weeks; third trimester, >27 weeks). Maternal outcomes included placental abnormalities, HELLP syndrome, deep vein thrombosis, pulmonary embolism, and maternal death. Fetal outcomes included pregnancy loss, intrauterine growth restriction, preterm birth, stillbirth, and admission to the NICU. Quantitative data were analyzed using a one-way ANOVA and are presented as mean ± standard deviation (SD). Nominal data were compared using chi-square or Fisher's exact tests and are reported as frequency (percent). Statistical significance was set at p < 0.05.
resultsA total of 289 COVID-affected pregnancies and 1706 non-COVID-19 pregnancies were included. Most patients, 189 (65.4%), were diagnosed with COVID-19 in the third trimester, 66 (22.8%) in the second trimester, and 34 (11.8%) in the first trimester. There was a statistically significant higher proportion of patients experiencing placental abnormalities in patients diagnosed with COVID-19 in the 3rd trimester with lowest occurrence in non-COVID-19 pregnancies, followed by patients diagnosed in the 1st and 2nd trimesters (p<0.001). Further, preterm delivery followed a similar frequency pattern, occurring most often in patients diagnosed with COVID-19 in the 3rd trimester (p<0.001).
conclusionPatients with COVID-19 infection in the third trimester of pregnancy face a heightened risk of adverse maternal-fetal outcomes. Further investigation into this relationship is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.